DE69938871D1 - Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen - Google Patents

Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen

Info

Publication number
DE69938871D1
DE69938871D1 DE69938871T DE69938871T DE69938871D1 DE 69938871 D1 DE69938871 D1 DE 69938871D1 DE 69938871 T DE69938871 T DE 69938871T DE 69938871 T DE69938871 T DE 69938871T DE 69938871 D1 DE69938871 D1 DE 69938871D1
Authority
DE
Germany
Prior art keywords
ctla
self antigens
stimulating
against self
cells against
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
DE69938871T
Other languages
English (en)
Inventor
James P Allison
Arthur A Hurwitz
Andrea Vanelsas
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of California
Original Assignee
University of California
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of California filed Critical University of California
Application granted granted Critical
Publication of DE69938871D1 publication Critical patent/DE69938871D1/de
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
DE69938871T 1998-12-03 1999-12-03 Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen Expired - Lifetime DE69938871D1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US11076198P 1998-12-03 1998-12-03
PCT/US1999/028739 WO2000032231A1 (en) 1998-12-03 1999-12-03 Stimulation of t cells against self antigens using ctla-4 blocking agents

Publications (1)

Publication Number Publication Date
DE69938871D1 true DE69938871D1 (de) 2008-07-17

Family

ID=22334796

Family Applications (1)

Application Number Title Priority Date Filing Date
DE69938871T Expired - Lifetime DE69938871D1 (de) 1998-12-03 1999-12-03 Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen

Country Status (11)

Country Link
EP (1) EP1137436B1 (de)
JP (1) JP5341287B2 (de)
AT (1) ATE397457T1 (de)
AU (1) AU774962B2 (de)
CA (1) CA2352783C (de)
CY (1) CY1108318T1 (de)
DE (1) DE69938871D1 (de)
DK (1) DK1137436T3 (de)
ES (1) ES2308857T3 (de)
PT (1) PT1137436E (de)
WO (1) WO2000032231A1 (de)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6682736B1 (en) 1998-12-23 2004-01-27 Abgenix, Inc. Human monoclonal antibodies to CTLA-4
US7109003B2 (en) 1998-12-23 2006-09-19 Abgenix, Inc. Methods for expressing and recovering human monoclonal antibodies to CTLA-4
US6984720B1 (en) * 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies
ES2402546T3 (es) * 2000-06-28 2013-05-06 Genetics Institute, Llc Moléculas PD-L2: nuevos ligandos de PD-1 y usos de lso mismos
JP4409430B2 (ja) 2002-07-03 2010-02-03 小野薬品工業株式会社 免疫賦活組成物
CN1240436C (zh) * 2002-08-28 2006-02-08 上海益众生物技术有限公司 成骨生长肽与粒细胞集落刺激因子在造血方面的协同作用
AU2004220036A1 (en) * 2003-03-12 2004-09-23 Duke University Oligonucleotide mimetics
US20040197312A1 (en) * 2003-04-02 2004-10-07 Marina Moskalenko Cytokine-expressing cellular vaccine combinations
US7494779B2 (en) 2004-06-14 2009-02-24 Li-Te Chin Method for producing human antibodies to human CD152 with properties of agonist, antagonist, or inverse agonist
CN117534755A (zh) 2005-05-09 2024-02-09 小野药品工业株式会社 程序性死亡-1(pd-1)的人单克隆抗体及使用抗pd-1抗体来治疗癌症的方法
EP1891107B1 (de) 2005-05-12 2011-07-06 ZymoGenetics, Inc. Zusammensetzungen und verfahren zur modulierung von immunreaktionen
BRPI0611766A2 (pt) 2005-06-08 2011-12-20 Dana Farber Cancer Inst Inc métodos e composições para o tratamento de infecções persistentes e cáncer por inibição da rota de morte celular programada
KR101888321B1 (ko) 2005-07-01 2018-08-13 이. 알. 스퀴부 앤드 선즈, 엘.엘.씨. 예정 사멸 리간드 1 (피디-엘1)에 대한 인간 모노클로날 항체
CN101325971A (zh) 2005-12-07 2008-12-17 米德列斯公司 Ctla-4抗体剂量递增方案
AU2009319701B2 (en) 2008-11-28 2014-10-09 Dana-Farber Cancer Institute, Inc. Methods for the treatment of infections and tumors
PL2482849T3 (pl) * 2009-09-30 2018-11-30 Memorial Sloan-Kettering Cancer Center Skojarzona immunoterapia w leczeniu nowotworu
CA2777226A1 (en) 2009-10-12 2011-04-21 Pfizer Inc. Cancer treatment
CN105457021A (zh) * 2012-05-04 2016-04-06 辉瑞公司 前列腺相关抗原及基于疫苗的免疫治疗疗法
WO2013169971A1 (en) 2012-05-10 2013-11-14 Bristol-Myers Squibb Company Anti-tumor antibodies as predictive or prognostic biomarkers of efficacy and survival in ipilimumab-treated patients
EP3049442A4 (de) 2013-09-26 2017-06-28 Costim Pharmaceuticals Inc. Verfahren zur behandlung von blutkrebs
AU2014360318B2 (en) 2013-12-05 2019-10-31 Rfemb Holdings, Llc Cancer immunotherapy by radiofrequency electrical membrane breakdown (RF-EMB)
JOP20200094A1 (ar) 2014-01-24 2017-06-16 Dana Farber Cancer Inst Inc جزيئات جسم مضاد لـ pd-1 واستخداماتها
JOP20200096A1 (ar) 2014-01-31 2017-06-16 Children’S Medical Center Corp جزيئات جسم مضاد لـ tim-3 واستخداماتها
CA2960824A1 (en) 2014-09-13 2016-03-17 Novartis Ag Combination therapies of alk inhibitors
PL3240801T3 (pl) 2014-12-31 2021-06-14 Checkmate Pharmaceuticals, Inc. Skojarzona immunoterapia nowotworów
ME03819B (de) 2015-03-23 2021-04-20 Jounce Therapeutics Inc Antikörper gegen icos
MA53355A (fr) 2015-05-29 2022-03-16 Agenus Inc Anticorps anti-ctla-4 et leurs procédés d'utilisation
TW201723190A (zh) 2015-10-22 2017-07-01 永斯醫療股份有限公司 用於測定icos表現之基因印記
US10149887B2 (en) 2015-10-23 2018-12-11 Canbas Co., Ltd. Peptides and peptidomimetics in combination with t cell activating and/or checkpoint inhibiting agents for cancer treatment
CN109069624A (zh) 2016-01-15 2018-12-21 瑞美控股有限责任公司 癌症的免疫治疗
BR112019011582A2 (pt) 2016-12-07 2019-10-22 Agenus Inc. anticorpos e métodos de utilização dos mesmos
SI3551660T1 (sl) 2016-12-07 2024-02-29 Agenus Inc. Protitelesa proti antictla-4 in načini njihove uporabe
CA3054928A1 (en) 2017-02-28 2018-09-07 Bristol-Myers Squibb Company Use of anti-ctla-4 antibodies with enhanced adcc to enhance immune response to a vaccine
JP7511478B2 (ja) 2018-04-09 2024-07-05 チェックメイト ファーマシューティカルズ ウイルス様粒子中へのオリゴヌクレオチドのパッケージ化
MA52289A (fr) 2018-04-18 2021-02-24 Xencor Inc Protéines de fusion fc hétérodimères il-15/il-15ra et leurs utilisations
MX2020010910A (es) 2018-04-18 2021-02-09 Xencor Inc Proteinas de fusion heterodimericas dirigidas a pd-1 que contienen proteinas de fusion il-15 / il-15ra fc y dominios de union al antigeno pd-1 y usos de los mismos.
US20210236694A1 (en) * 2018-05-03 2021-08-05 The Johns Hopkins University Induction of anti-tumoral immune microenvironments
US11358999B2 (en) 2018-10-03 2022-06-14 Xencor, Inc. IL-12 heterodimeric Fc-fusion proteins
MA53862A (fr) 2018-10-12 2022-01-19 Xencor Inc Protéines de fusion fc d'il-15/il-15ralpha ciblant pd-1 et utilisations dans des polythérapies faisant intervenir celles-ci
CN115916233A (zh) 2019-10-03 2023-04-04 Xencor股份有限公司 靶向IL-12异源二聚体Fc融合蛋白
TW202128757A (zh) 2019-10-11 2021-08-01 美商建南德克公司 具有改善之特性的 PD-1 標靶 IL-15/IL-15Rα FC 融合蛋白
JP7405361B2 (ja) 2019-10-21 2023-12-26 東亞合成株式会社 抗腫瘍ペプチドおよびその利用
JP7498889B2 (ja) 2020-01-30 2024-06-13 東亞合成株式会社 Ｃｔｌａ４とｂ７タンパク質との結合を抑制するペプチドおよびその利用
WO2024163477A1 (en) 2023-01-31 2024-08-08 University Of Rochester Immune checkpoint blockade therapy for treating staphylococcus aureus infections

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL92382A (en) * 1988-11-23 1994-12-29 Univ Michigan Use of a ligand specific for CD28 in the manufacture of medicament
US5811097A (en) * 1995-07-25 1998-09-22 The Regents Of The University Of California Blockade of T lymphocyte down-regulation associated with CTLA-4 signaling
AU6703198A (en) * 1997-03-21 1998-10-20 Brigham And Women's Hospital Immunotherapeutic ctla-4 binding peptides
US6984720B1 (en) * 1999-08-24 2006-01-10 Medarex, Inc. Human CTLA-4 antibodies

Also Published As

Publication number Publication date
CY1108318T1 (el) 2014-02-12
JP2002531416A (ja) 2002-09-24
AU2164900A (en) 2000-06-19
AU774962B2 (en) 2004-07-15
DK1137436T3 (da) 2008-10-13
ES2308857T3 (es) 2008-12-01
PT1137436E (pt) 2008-09-15
ATE397457T1 (de) 2008-06-15
CA2352783C (en) 2012-04-10
EP1137436A1 (de) 2001-10-04
CA2352783A1 (en) 2000-06-08
WO2000032231A1 (en) 2000-06-08
JP5341287B2 (ja) 2013-11-13
EP1137436B1 (de) 2008-06-04

Similar Documents

Publication Publication Date Title
DE69938871D1 (de) Stimulierung von T-Zellen gegen Selbstantigene unter Verwendung von CTLA-4 inhibierenden Wirkstoffen
CY1121113T1 (el) Θεραπεια της νοσου ρομρε
ES2163034T3 (es) Composiciones micelares de copolimeros de bloque de polieter, para la objetivizacion de agentes biologicos como diana.
DE59611341D1 (de) Verwendung von saccharid-konjugaten
CY1106046T1 (el) Μεθοδος για την θεραπευτικη αγωγη ινωσεως με χρησιμοποιηση ενος ανταγωνιστου της αλφα-4-υπομοναδος της ιντεγκρινης
BR0113491A (pt) Polinucleotìdeo e polipeptìdeo isolados, vetor de expressão, célula hospedeira, proteìna de fusão, métodos para estimular e/ou expandir células t especìficas para uma protéina de tumor, para estimular uma resposta imune em um paciente, para o tratamento de um câncer em um paciente e para inibir o desenvolvimento de um câncer em um paciente, população de célula t isolada, composição, e, uso de um componente.
ATE239474T1 (de) Verwendung von levobupivacain
NO971341L (no) Promoter for reseptor tyrosinkinase TIE
DK0952772T3 (da) Fremgangsmåder til anvendelse af mononukleare phagocytter til at fremme axonal regeneration
DE69621243D1 (de) Verwendung von bradykininantagonisten zur induzierung oder stimulation des haarwachstums und/oder zur verlangsamung des haarausfalls
DK0855916T3 (da) Farmaceutisk præparat indeholdende en Activin-stimulator
DK0768886T3 (da) Endothelforingseffekter og behandling af vasospastiske lidelser
DE69733557D1 (de) Endothelin-antagonisten zur behandlung von herzversagen
ES2154290T3 (es) Estimulacion de la diferenciacion celular por sindecano.
IL131478A0 (en) Methods for treatment of scar tissue
TR200501763T2 (tr) Tedavi ve ilaç tarama yöntemleri
MX9803610A (es) Utilizacion de flupirtina para la profilaxis y la terapia de enfermedades que van a compañadas de un deterioro del sistema celular hermatopoyetico.
EA200000909A1 (ru) ФОРМА VI 5,6-ДИХЛОР-2-(ИЗОПРОПИЛАМИНО)-1-(b-L-РИБОФУРАНОЗИЛ)-1H-БЕНЗИМИДАЗОЛА
PT862454E (pt) Novas utilizacoes de ctla-8 de mamifero e reagentes relacionados
HK1046847B (zh) 包括撲熱息痛和丁螺環酮的止痛藥物組合
DK1007085T3 (da) Anvendelse af væksthormon i præparater til behandling af insulin-resistens i hjertet
TR200000728T2 (tr) Kronik hepatit C' nin tedavisinde IFN-alfa ve amantadin kullanımı.
DE69724228D1 (de) Kombinationstherapie von topoisomerase ii toxinen und bis-dioxypiperazinderivaten
PT958290E (pt) Derivados de 1,4-di-hidropiridina e seu uso em terapia
UA32241A (uk) Спосіб лікування запалювальних процесів у експериментальних тварин

Legal Events

Date Code Title Description
8364 No opposition during term of opposition